The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease.
The molecular genetic basis that leads to Lewy Body (LB) pathology in 15-20% of Alzheimer disease cases (LBV/AD) was largely unknown. Alpha-synuclein (SNCA) and Leucine-rich repeat kinase2 (LRRK2) have been implicated in the pathogenesis of Parkinson's disease (PD), the prototype of LB spectrum disorders. We tested the association of SNCA variants with LB pathology in AD. We then stratified the SNCA association analyses by LRRK2 genotype. We also investigated the expression regulation of SNCA and LRRK2 in relation to LB pathology. We evaluated the differences in SNCA-mRNA and LRRK2-mRNA levels as a function of LB pathology in the temporal cortex (TC) from autopsy-confirmed LBV/AD cases and AD controls. We further investigated the cis-effect of the LB pathology-associated genetic variants within the SNCA and LRRK2 loci on the mRNA expression of these genes. SNCA SNPs rs3857059 and rs2583988 showed significant associations with increased risk for LB pathology. When the analyses were stratified by LRRK2-rs1491923 genotype, the associations became stronger for both SNPs and an association was also observed with rs2619363. Expression analysis demonstrated that SNCA- and LRRK2-mRNA levels were significantly higher in TC from LBV/AD brains compared with AD controls. Furthermore, SNCA-mRNA expression level in the TC was associated with rs3857059; homozygotes for the minor allele showed significant higher expression. LRRK2-transcript levels were increased in carriers of rs1491923 minor allele. Our findings demonstrated that SNCA contributes to LB pathology in AD patients, possibly via interaction with LRRK2, and suggested that expression regulation of these genes may be the molecular basis underlying the observed LB associations.
Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA.
Colton
C
Linnertz
Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA, Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710, USA.
Michael W
MW
Lutz
Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA.
John F
JF
Ervin
Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27708, USA.
Jawara
J
Allen
Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27708, USA.
Natalie R
NR
Miller
Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710, USA.
Kathleen A
KA
Welsh-Bohmer
Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA, Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710, USA, Zinfandel Pharmaceuticals, Chapel Hill, NC, USA and.
Allen D
AD
Roses
Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA, Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710, USA, Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27708, USA o.chibafalek@duke.edu.
Ornit
O
Chiba-Falek
D000544:Alzheimer Disease / Q000235:genetics* / Q000473:pathology*; D001344:Autopsy; D016022:Case-Control Studies; D056726:Genetic Association Studies; D014644:Genetic Variation; D006801:Humans; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D016631:Lewy Bodies / Q000235:genetics / Q000473:pathology*; D020641:Polymorphism, Single Nucleotide; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D013702:Temporal Lobe / Q000378:metabolism; D051844:alpha-Synuclein / Q000235:genetics*
C497604:SNCA protein, human; D051844:alpha-Synuclein; C495280:LRRK2 protein, human; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D017346:Protein Serine-Threonine Kinases